National Institute of Allergy & Infectious Diseases: Monoclonal Antibody Reduces Asthma Attacks in Urban Youth
August 10, 2022
August 10, 2022
WASHINGTON, Aug. 10 (TNSjou) -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release on Aug. 10, 2022:
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found. This population . . .
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found. This population . . .